Cediranib: A Potent VEGFR Inhibitor
Exploring the anti-cancer potential of a key pharmaceutical compound.
Get a Quote & SampleProduct Core Value
Cediranib
Cediranib is a powerful inhibitor targeting Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinases. Its primary role is as an antineoplastic agent, investigated for its efficacy in treating various cancers by hindering tumor angiogenesis and proliferation.
- Discover the potential of Cediranib for cancer treatment and its application as a pharmaceutical powder.
- Understand the mechanism of action of this potent VEGF receptor tyrosine kinase inhibitor.
- Learn about the usage of Cediranib CAS 288383-20-0 in research and development settings.
- Explore the benefits of this Antineoplastic Agent Cediranib in targeted therapies.
Key Advantages
Targeted Action
Cediranib effectively inhibits VEGF receptor tyrosine kinases, offering a targeted approach to cancer therapy, a crucial aspect when considering VEGFR Inhibitor applications.
Oral Bioavailability
As an orally administered agent, it provides a convenient option for patients undergoing cancer treatment, enhancing patient compliance and accessibility for Cediranib pharmaceutical powder.
Research Utility
Its well-defined mechanism makes it a valuable tool in oncology research, particularly for studying angiogenesis and developing new treatment strategies for various cancers, highlighting its role as a VEGF Inhibitor.
Key Applications
Cancer Therapy
Used in the research and development of treatments for various malignancies, leveraging its capabilities as an Antineoplastic Agent Cediranib.
Angiogenesis Inhibition
Its primary mechanism involves inhibiting new blood vessel formation in tumors, a critical factor in Cediranib for cancer treatment.
Drug Discovery Research
Serves as a vital compound for exploring new drug combinations and treatment protocols in oncology, reinforcing its importance as a VEGF receptor tyrosine kinase inhibitor.
Pharmaceutical Development
As a high-purity raw material, it is essential for pharmaceutical companies developing advanced cancer therapies, utilizing Cediranib CAS 288383-20-0.